Author of

• 18718

  +

  P3.05 - Poster Session with Presenters Present (ID 475)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Palliative Care/Ethics
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 18725

    +

    P3.05-007 - Prospective Evaluation for Combination Antiemetic Therapy on CINV in NSCLC Receiving Carboplatin-Based Chemotherapy of MEC (ID 3737)

    14:30 - 14:30  |  Author(s): K. Aiba
    • Abstract
    • Slides

    Background:
    The incidence of delayed chemotherapy-induced nausea and vomiting (CINV) for non-small cell lung cancer (NSCLC) patients receiving carboplatin (CBDCA) -based chemotherapy (CBDCA+pemetrexed (PEM) / CBDCA+ paclitaxel (PTX)) has not been clearly controlled.
    
    Methods:
    We used the combined data from the two prospective observational studies; A nationwide survey of CINV study group and the other prospective observational study in Japan. We assessed whether delayed CINV were controlled with combination antiemetic treatment. We also evaluate risk factors by logistic regression analysis.
    
    Results:
    A total of 240 patients were evaluable in this study. The median age was 66 (range:34-82) with 173 males and 67 females. Three antiemetics were used in 54 (22.5%) patients. Delayed nausea and vomiting were experienced more commonly in women than in men. Delayed nausea was well controlled with 3 antiemetics than with 2 antiemetics for women (45.0% vs. 72.3%; P=0.0506). Delayed vomiting was well controlled with 3 antiemetics than with 2 antiemetics for overall (11.1% vs. 23.1%; P=0.0571) and for women (20.0% vs. 44.7%; P=0.0962). We identified several risk factors; women (OR=2.903 ;95% confidence interval [CI], 1.607-5.242 ;P=0.0004) and age (OR=0.968 ;95%CI, 0.938-0.999 ;P=0.0442) for delayed nausea, and women (OR=4.252 ;95%CI, 2.154-8.394 ;P<0.0001) and 2 antiemetics (OR=3.140 ;95%CI, 1.205-8.179 ;P=0.0192) for delayed vomiting.
    
    Conclusion:
    Three antiemetics combination are encouraged for NSCLC patients treated with CBDCA-based chemotherapy to alleviate delayed vomiting.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.